Cleveland BioLabs, Inc. (NASDAQ:CBLI) Short Interest Down 13.6% in August

Cleveland BioLabs, Inc. (NASDAQ:CBLI) was the recipient of a significant decrease in short interest in August. As of August 31st, there was short interest totalling 24,700 shares, a decrease of 13.6% from the July 31st total of 28,600 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average daily volume of 4,900 shares, the short-interest ratio is presently 5.0 days.

Shares of NASDAQ:CBLI remained flat at $$1.02 during trading on Friday. 4,588 shares of the stock were exchanged, compared to its average volume of 7,949. Cleveland BioLabs has a twelve month low of $1.00 and a twelve month high of $2.16. The stock has a 50 day moving average of $1.41 and a 200-day moving average of $1.51.

Cleveland BioLabs (NASDAQ:CBLI) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.05) earnings per share for the quarter. Cleveland BioLabs had a negative net margin of 304.43% and a negative return on equity of 96.01%. The firm had revenue of $0.28 million during the quarter.

Separately, ValuEngine upgraded shares of Cleveland BioLabs from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

Cleveland BioLabs Company Profile

Cleveland BioLabs, Inc, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines.

Read More: What is the Current Ratio?

Receive News & Ratings for Cleveland BioLabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs and related companies with MarketBeat.com's FREE daily email newsletter.